Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

With Trump's backing, the pharma industry is leaning into the idea of more "direct-to-consumer" sales. But experts say the ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

The U.S. government announced funding cuts to mRNA vaccine research. What is the impact on American healthcare and biotech?

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...